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BH3 mimeticThe BH3-only proteins of Bcl-2 family are essential initiators of apoptosis that propagate extrinsic and
intrinsic cell death signals. The interaction of BH3-only proteins with other Bcl-2 family members is critical for
understanding the core machinery that controls commitment to apoptosis by permeabilizing the
mitochondrial outer membrane. BH3-only proteins promote apoptosis by both directly activating Bax and
Bak and by suppressing the anti-apoptotic proteins at the mitochondria and the endoplasmic reticulum. To
prevent constitutive cell death, BH3-only proteins are regulated by a variety of mechanisms including
transcription and post-translational modiﬁcations that govern speciﬁc protein–protein interactions.
Furthermore, BH3-only proteins also control the initiation of autophagy, another important pathway
regulating cell survival and death. Emerging evidence indicates that the interaction of BH3-only proteins with
membranes regulates binding to other Bcl-2 family members, thereby specifying function. Due to the
important role of BH3-only proteins in the regulation of cell death, several promising BH3-mimetic drugs that
are active in pre-clinical models are currently being tested as anti-cancer agents. This article is part of a Special
Issue entitled Mitochondria: the deadly organelle.ondria: the deadly organelle.
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Apoptosis is a form of programmed cell death that senses and
purges developmentally excess, mutated and damaged cells. Apopto-
sis differs from other forms of programmed cell death by eliminating
the target cells without eliciting inﬂammation. Studies in Caenorhab-
ditis elegans, Drosophila melanogaster and mammals have shown that
it is an evolutionary conserved process that is tightly regulated and
required for the proper development and homeostasis of multi-
cellular organisms. Accordingly, deregulation in apoptosis causes
several important pathological processes. For example, tumour cells
accumulate mutations that allow them to bypass apoptosis during
clonal expansion, whereas the effects of stroke and many neurode-
generative diseases are mediated by neuronal apoptosis.
In mammals, apoptosis is initiated by two different pathways: one
when cells receive intrinsic death stimuli such as excessive oncogene
activation, DNA damage, or the unfolded protein response (UPR), and
the other in response to extrinsic death stimuli such as the
engagement of the Fas or TNFα ligands to their receptors on cell
surface as part of the effector phase of an immune response. These
pathways converge at the mitochondrial outer membrane (MOM)
where the Bcl-2 protein family plays a pivotal role in the regulation of
apoptosis. The family consists of more than 20 members with eitherpro-apoptotic or anti-apoptotic functions and is divided into three
groups based on the presence of conserved Bcl-2 homology (BH)
regions. Themulti-region anti-apoptotic proteins Bcl-2, Bcl-XL, Bcl-W,
Mcl-1 and A1 contain all four BH regions. The pro-apoptotic proteins
are divided into two groups. The multi-region pro-apoptotic proteins,
Bax, Bak and Bok were conventionally thought to share BH 1–3
regions, whereas the BH3-only proteins were proposed to share
homology in the BH3 region only. Members of this diverse subset
include Bad, Bim, Bid, Noxa, Puma, Bik/Blk, Bmf, Hrk/DP5, Beclin-1 and
Mule (See Table 1) [1]. Recent results described below suggest this
may be an over-simpliﬁed view.
Studies from C. elegans, knock-out mice and mammalian cell-lines
have shown that BH3-only proteins are essential initiators of intrinsic
apoptosis. BH3-only proteins monitor many cellular processes and
transmit both intrinsic and extrinsic death signals to the multi-region
Bcl-2 family proteins at the MOM. BH3-only proteins inhibit the anti-
apoptotic proteins and activate the pro-apoptotic proteins to cause
mitochondrial outer membrane permeabilization (MOMP) [2]. As a
consequence of MOMP, mitochondrial inter membrane space proteins
such as cytochrome c and SMAC are released into the cytoplasm. Once
in the cytoplasm, these proteins activate or de-repress caspases which
proteolyse a distinct cohort of proteins that cause the morphologic
and functional features of apoptosis and eliminate the cell. As the
main regulator of this ﬁnal effector phase, MOMP represents the
commitment step to apoptosis and thus is often the ‘point-of-no-
return’ for a cell. Therefore studying the mechanisms of activation or
inhibition of the membrane permeabilizing proteins Bax and Bak and
Table 1
Localization and targeting mechanisms of BH3-only proteins.
BH3-only
protein
Cellular localization Targeting mechanism Refs
Activator BH3-only proteins
Bim Associated with
microtubules in healthy
cells; localizes
predominantly to
mitochondria and also to
intracellular membranes
when over-expressed in
apoptotic cells
C-terminal hydrophobic
segment using TOM
complex
[26,44]
Bid Cytosolic and nuclear in
healthy cells; localizes to
Mitochondria and ER upon
cleavage by caspase-8 on
the onset of apoptosis
Membrane binding helix 6
and 7
[48,49,59]
Puma MOM Unknown; C-terminal
hydrophobic segment (?)
[60]
Sensitizer BH3-only proteins
Bad Cytosolic in healthy cells,
mitochondrial in apoptotic
cells
Two lipid binding domains
at C-terminus
[46]
Noxa Mitochondria Mitochondrial targeting
region at C-terminus and
BH3 region
[57,58]
Bik/Blk ER C-terminal hydrophobic
segment
[45]
Bmf Myosin V motors by
association with dynein
light chain 2 in healthy
cells, and mitochondria
upon induction of
apoptosis.
Unknown; maybe through
association with Bcl-2
members
[61]
Hrk/DP5 Predominantly localized to
mitochondria
C-terminal hydrophobic
segment
[62]
Beclin-1 ER, mitochondria, trans
Golgi network
Unknown [63]
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molecules that modify these processes is an important goal for
researchers and pharmaceutical companies. Here we describe the
structural and evolutionary relationship of BH3-only proteins to the
Bcl-2 family and the biochemical function of BH3-only proteins as
postulated by three different models of the regulation of apoptosis.
We will discuss several topics that are the focus of ongoing research
including: the role of membrane binding in modifying BH3-only
protein structure and function, how BH3-only proteins activate the
multi-region pro-apoptotic proteins, why there are so many BH3-only
proteins, where they act and the emerging role of BH3 mimetic drugs
as anti-cancer agents.2. Evolution and structure of BH3-only proteins
The ﬁrst evidence for the genetic basis for apoptosis came from C.
elegans, in which four genes Egl-1, Ced-3, Ced-4 and Ced-9 altered the
cell death phenotype prior to engulfment by neighbouring cells [3].
Shortly after, mammalian homologues of these genes were identiﬁed
as part of a large network.While C. elegans has one homologue each of
Ced-9 and Egl-1, human has 13 Ced-9 homologues (multi-region Bcl-2
proteins) and a number of highly divergent proteins that are
analogous to Egl-1 (BH3-only protein). Within the Bcl-2 family, the
evolutionary relationship between multi-region Bcl-2 family mem-
bers and BH3-only proteins (other than Bid) is distant. The multi-
region Bcl-2, Bcl-XL, Bax and Bid share a common origin, and other
BH3-only proteins evolved later [4]. Bid may be an outlier in the BH3-
only family, as it shares phylogenetic, structural and functional
features with Bax [5].Despite opposing functions and little shared sequence homology
(other than the conserved BH regions), many Bcl-2 family proteins
share a similar structure. The three-dimensional structures of Bcl-2
family proteins resemble membrane insertion domains of diphtheria
toxins and colicins suggesting a role in pore formation in membranes
[6]. However, of all the BH3-only proteins studied to date, only Bid
shows a deﬁned structure [7,8]. Other BH3-only proteins are
intrinsically unstructured and only attain a structured BH3 region
after binding to multi-region Bcl-2 partners [9]. This theme of
dynamic conformation change with function will be examined in
other contexts in subsequent sections.
3. Assigning a role: how do BH3-only proteins turn on apoptosis
It is now widely acknowledged that activation of either of the pro-
apoptotic proteins, Bax and Bak leads to MOMP [10], and several
different models have been proposed to explain the role of anti-
apoptotic and BH3 proteins in this process. A signiﬁcant point of
contention between the original versions of the models is whether
BH3-only proteins promote apoptosis by directly or indirectly
activating Bax and Bak.
3.1. Direct activation model
The direct activation model postulates that BH3-only proteins
directly bind to and interact with Bax and Bak to promote MOMP.
Furthermore, BH3-only proteins can be classiﬁed as either activators
or sensitizers [11] (Fig. 1A). Despite sharing sequence homology in
the BH3 region and occupying the same hydrophobic pocket on anti-
apoptotic proteins, each BH3-only protein selectively binds a deﬁned
range of anti-apoptotic proteins. The activators Bim, tBid and
potentially Puma bind all ﬁve anti-apoptotic proteins. By contrast,
the sensitizers Bad and Bmf bind Bcl-2, Bcl-XL and Bcl-W; Bik and Hrk
bind Bcl-XL, Bcl-W and A1; and Noxa only binds to Mcl-1 and A1
[11,12]. In a healthy cell, BH3-only proteins are either inactive or are
sequestered by anti-apoptotic proteins to keep apoptosis at bay. In
response to an apoptotic signal, the activator BH3-only proteins are
either activated through multiple mechanisms (transcriptional, post-
transcriptional and post-translational), or are released from the anti-
apoptotic proteins by being displaced by sensitizer BH3 proteins that
bind to anti-apoptotic proteins with higher afﬁnity. Once “freed”,
these activators can bind to Bax or Bak [13].
Thus in this model, anti-apoptotic proteins function by binding to
and sequestering the activator BH3-only proteins and not by binding
directly to Bax or Bak [13], as activator BH3-only proteins Bim, tBid
and Puma BH3 peptides and full-length versions bind to puriﬁed Bcl-
2, Bcl-XL, Mcl-1, Bcl-W and A1 in vitro [11,13,14] (Fig. 1A). Both Bid
and Bim bind to and are sequestered by anti-apoptotic proteins [15–
17], and tBid induced permeabilization of liposomes and isolated
mitochondria is inhibited by Bcl-2, Bcl-XL, Bcl-W, Mcl-1 and Bﬂ-1
[14,18–21].
Activator BH3-only proteins, Bid and Bim also bind to and induce
conformational changes leading to the activation of Bax and Bak
[13,22]. BH3 peptides of Bid and Bim induce Bax activation and
membrane permeabilization in liposomes and mitochondria [11,23].
Recombinant tBid has been shown to cause insertion and oligomer-
ization of Bax and Bak in artiﬁcial membranes and isolated
mitochondria [20,24]. The role of recombinant Bim as an activator
BH3-only protein comes from studies done using the different splice
isoforms of Bim: BimS, BimL, BimEL and BimAD.While BimEL has been
shown to activate Bax to release cytochrome c from isolated
mitochondria, in the same study BimL was unable to do so [25].
BimS and BimAD isoforms have also been shown to promote
membrane permeabilization by activating Bax [26,27]. While the
role of Bid and Bim is well established in this model, the role of Puma
Fig. 1. Overview of the three models of regulation of apoptosis by Bcl-2 family proteins.
BH3-S and BH3-A represent sensitizer and activator BH3-only proteins, respectively.
A) The Direct activation model proposes that activator BH3-only proteins are required
for activating Bax and Bak. Anti-apoptotic proteins inhibit the activator BH3-only
proteins but not Bax and Bak to suppress apoptosis. Sensitizer BH3-only proteins
displace the activator BH3-only proteins from the anti-apoptotic proteins to promote
apoptosis. B) The Displacement model postulates that Bax and Bak are constitutively
active in cells and must be sequestered by anti-apoptotic proteins for cell survival. BH3-
only proteins only play the sensitizer role and inhibit their respective anti-apoptotic
proteins to promote apoptosis. Both the direct activation and the displacement model
do not deﬁne a role for the membrane. C) Embedded together model highlights the
active role of the membrane where Bcl-2 family proteins insert into and change their
conformations that dictate their functions. Cytoplasmic anti-apoptotic proteins are
recruited to membranes and are activated by both sensitizer and activator BH3-only
proteins as well as Bax/Bak. At the membrane, anti-apoptotic proteins inhibit the
activator BH3-only proteins and Bax/Bak to prevent MOMP. Sensitizer BH3-only
proteins displace the activator BH3-only proteins and Bax/Bak from the anti-apoptotic
proteins to promote apoptosis. Activator BH3-only proteins recruit Bax to the
membrane to induce MOMP and apoptosis. These interactions are reversible and are
governed by equilibrium constants that are altered by the concentrations and
interactions of the proteins with each other and with membranes.
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activator [13,28–30] and a sensitizer in different studies [14,31–33].
Sensitizer BH3-only proteins, such as Bad, Noxa, Bik, Bmf, Beclin-1,
and Hrk function by liberating BH3-only activators from the anti-
apoptotic proteins, and consequently promoting the activation of Bax
and Bak. Therefore sensitizer BH3-only proteins indirectly promote
MOMP, as they do not directly activate Bax or Bak [11,14,31] (Fig. 1A).
Due to the distinct pattern of interaction with anti-apoptotic proteins,
joint expression of Bad and Noxa is required for a cell to promote
apoptosis in cells expressing Mcl-1 and Bcl-2.
3.2. Displacement model
The displacement model (or the indirect activation model)
proposes that Bax and Bak are constitutively active and therefore
must be inhibited by the anti-apoptotic proteins for the cell to survive.
To initiate apoptosis, BH3-only proteins displace Bax and Bak from the
anti-apoptotic proteins to promote Bax or Bak mediated MOMP
(Fig. 1B). Since BH3-only proteins selectively interact with a speciﬁc
spectrum of anti-apoptotic proteins, a combination of BH3-only
proteins is required to induce apoptosis in cells expressing multiple
anti-apoptotic Bcl-2 family members [12]. In the displacement model,anti-apoptotic proteins directly bind Bax and Bak for their inhibition,
and BH3-only proteins do not directly bind to Bax and Bak to cause
their activation.
In support of the displacement model, peptides derived from
different BH3-only proteins display vastly different afﬁnities for
different anti-apoptotic proteins measured in solution or on a solid
support [12]. In addition, BH3 peptides of multi-region pro-apoptotic
proteins form complexes with anti-apoptotic proteins: Bak BH3
peptide and endogenous protein in cells selectively complex with Bcl-
XL and Mcl-1, but not with Bcl-2, Bcl-W or A1 [34]. After apoptosis
induction, Noxa binds to Mcl-1 thereby disrupting the Mcl-1–Bak
complex and displacing Bak and promoting both Mcl-1 degradation
and apoptosis [34]. Similarly, Bik displaces activated Bak from Mcl-1
and Bcl-XL [35]. Furthermore, Bax and Bak promote apoptosis in cells
with no Bim or Bid and reduced Puma, leading the authors to conclude
that the multi-region pro-apoptotic proteins are always active in the
cells [36]. However, the activity of the residual Puma or the presence
of other factors (such as p53 and Drp1) cannot be ruled out as possible
activators of Bax or Bak in this context. Furthermore, the BH3 stapled
peptide of Bim has been demonstrated to bind to Bax [37].
3.3. Embedded Together model
While the original versions of the direct activation and the
displacement models proposed different functions for the anti-
apoptotic proteins, both suggested that speciﬁcity was achieved via
the differences in the afﬁnity of BH3 proteins for anti-apoptotic
proteins. The studies reporting the afﬁnities of the various interac-
tions were based on measurements of binding partners in solution or
attached to a surface and thus in these models the membrane
functions only as a passive recipient for the Bcl-2 proteins. We
proposed a model termed “Embedded Together” to account for the
consequences of these interactions occurring in and on membranes,
which is the “locus of action” for apoptosis in cells. The ultimate
outcome is therefore determined by the competing equilibria and the
relative concentrations of binding partners [38–40] (Fig. 1C).
The most obvious consequence of the interactions between the
different Bcl-2 family proteins taking place in the lipid bilayer is the
inevitable change in the conformation of the proteins in a lipid
environment. In an apoptotic cell, activator BH3-only proteins are
required to interact with Bax and Bak at the MOM and the
endoplasmic reticulum (ER). Both the activator and sensitizer BH3-
only proteins recruit and activate anti-apoptotic proteins by changing
their conformation at membranes. Once at the membrane, the anti-
apoptotic proteins not only sequester the activator BH3-only proteins
to prevent Bax and Bak activation but also bind and inhibit activated
Bax and Bak in the membrane. Furthermore, sensitizer BH3-only
proteins neutralize the function of the anti-apoptotic proteins by
displacing both the activators and Bax or Bak from the membrane
embedded conformers of the anti-apoptotic proteins. Because the
protein conformations are critically modiﬁed by the presence of the
membrane, the membrane is thus a partner rather than a “passive
recipient” in the process (Fig. 1C).
Consistent with the Embedded Together model, the interaction of
tBid with Bcl-2 in the MOM causes a conformational change in Bcl-2
(discussed later) [41] that strongly correlates with its anti-apoptotic
activity [21]. In addition, only themembrane bound form of tBid binds
to Bax [24], after which Bax undergoes at least two conformational
changes: insertion into the membrane and exposure of the 6A7
epitope, before oligomerization andmembrane permeabilization [22].
Using an in vitro system of puriﬁed proteins, liposomes and
mitochondria, Bax activation has been shown to proceed via an
ordered series of events: ﬁrst tBid binds to the membrane which then
recruits Bax to permeabilize the membrane. Bcl-XL inhibits recruit-
ment of Bax to the membrane, whereas Bad neutralizes the effects of
Bcl-XL and thereby promotes tBid and Bax mediated permeabilization
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Bax equivalently in membranes [20], reconciling proposals of both the
direct activation and displacement models. Recent experiments with
knock-in mice in which the BH3 region of Bim was replaced with that
of Bad, Noxa or Puma indicate that for the complete pro-apoptotic
function of Bim, both engagement of all anti-apoptotic proteins, as
well as activation of Bax is required [42]. This in vivo study conﬁrms
the multiple functions of BH3-only proteins as proposed by the
Embedded Together model.
4. Getting to work: how do BH3-only proteins bind tomembranes?
After activation, BH3-only proteins are located at mitochondrial
and/or ER membranes. Targeting of BH3-only proteins to these
membranes is necessary for the activation of Bax or Bak and the
ampliﬁcation of death signals. However, the exact mechanism by
which speciﬁc BH3-only proteins migrate to and insert into
membranes varies (Table 1). For example, Noxa contains a sequence
of conserved amino acids found in non BH3-only proteins, that
appears to be a mitochondrial targeting region at its C-terminus [43].
Some BH3-only proteins such as Bim, Puma, Bik and HRK have a C-
terminal hydrophobic segment of amino acids known as a tail-anchor
sequence. Tail-anchor sequences are necessary and sufﬁcient in
determining the sub-cellular location of proteins. The function of
the tail-anchor sequence has been examined for Bim [26,44] and Bik
[45]. Other BH3-only proteins, such as Bid, Bad and Beclin-1 lack an
identiﬁable tail-anchor sequence but contain other types of hydro-
phobic sequences. These sequences presumably target to the MOM
and/or ER by other mechanisms, including spontaneous partitioning
into the lipid bilayer as we and others have observed using in vitro
systems [19,24,46]. However, other factors maymodulate this process
in vivo. For example, various phosphorylation sites on Bad are known
to inﬂuence sub-cellular localization [47], and cleavage of Bid by
caspases is required before the p15 fragment (tBid) can bind to
membranes [48,49].
Multiple Bcl-2 family proteins have been reported to interact with
different lipids when targeted tomembranes. Cardiolipin, a negatively
charged lipid speciﬁc to mitochondria generated considerable interest
when it was shown to mediate the speciﬁc targeting of tBid to MOM
[19,50]. Furthermore, interaction of tBid with cardiolipin was
proposed to occur at mitochondrial contact sites and cause mito-
chondrial cristae reorganization [51,52]. However, the role of
cardiolipin for mediating targeting of tBid to the MOM has been
disputed. Some experiments suggest that the overall negative charge
of the lipid membrane, and not the individual lipids target tBid to
liposomes [53]. Because a complete knock-down of cardiolipin would
be fatal, in vitro studies are needed to examine the interaction
between cardiolipin and tBid. Similarly, two lipid binding regions
have been identiﬁed in Bad, one of which confers binding to
cholesterol and the other to negatively charged lipids [46]. In its
non-apoptotic phosphorylated form, Bad accumulates in raft micro-
domains of MOM, whereas when it is dephosphorylated, Bad
translocates to the negatively charged MOM and exerts its pro-
apoptotic effects. The authors suggested that binding of Bad is a
prerequisite for the recruitment of Bcl-XL to the MOM.
In addition to different lipids facilitating the targeting of BH3-only
proteins to membranes, protein factors that mediate binding of BH3-
only proteins to mitochondria or ER are also being identiﬁed. Recently
the membrane protein MTCH2/MIMP has been discovered as a major
facilitator of tBid insertion into the MOM [54]. Using cell lines
generated from knock-out mouse embryos and a conditional knock
out mouse model, a marked decrease in tBid recruitment to the MOM
was observed. MTCH2/MIMP shares considerable homology with the
mitochondrial-carrier domain (MCD) of the mitochondrial nucleotide
transporter ANT1 and in the predicted structure of the whole protein
[55]. ANT1 is located in the mitochondrial inner membrane and hasthree MCDs, each of which binds to two molecules of cardiolipin. We
speculate that MTCH2/MIMP, containing one MCD, binds to two
molecules of cardiolipin at the MOM. Thus MTCH2/MIMP may
enhance tBid function by facilitating interactions with cardiolipin
rich regions. Alternatively, MTCH2/MIMP may act as a receptor (or
help assemble a receptor) for tBid as its mechanism of action. Further
studies in this area will be useful in suggesting candidates for cognate
factors that may be involved in the membrane targeting of Noxa and
Bad.
Numerous studies have reported that the spontaneous membrane
binding of tBid causes the migration of soluble Bax and Bcl-XL to the
membranes [19,20,24,56]. In these in vitro systems, the rate of
spontaneous insertion of Bax and Bcl-XL intomembranes is negligible,
and tBid binds to both proteins very weakly in solution. Therefore, the
most likely scenario is that soluble Bax and Bcl-XL interact with
membrane-bound tBid and undergo conformational change(s) that
facilitates their insertion into membranes. Similarly, Bad and Bim can
cause the insertion of soluble Bcl-XL and Bax into membranes,
respectively. It is possible that a reciprocal process occurs for other
BH3-only proteins. Thus the multi-region, membrane resident Bcl-2
family proteins such as Bak, Bcl-2 andMcl-1may enhance or cause the
binding of some BH3-only proteins to membranes. A few examples of
the different possible scenarios that may be relevant for different
BH3-only proteins include: ﬁrst, by binding to membrane-resident
proteins through the BH3 region, the BH3-only proteins may be “held
in place” in close proximity (but not inserted into membranes) in the
same conformation as the soluble form so that inefﬁcient spontaneous
insertion becomes more likely. Second, binding to multi-region Bcl-2
family members may induce a conformational change in the BH3-only
protein thereby allowing membrane insertion. For example, Noxa
requires both the MTD and the BH3 region for proper targeting to the
MOM and cytochrome c release (reviewed in [57]). Mitochondrial
localization of mouse Noxa was abolished by mutating the two BH3
regions, indicating that targeting of Noxa to the MOM is contingent on
functional BH3 regions [58]. We speculate that the BH3 region of Noxa
may ﬁrst interact with Mcl-1 or A1 at the membrane, thereby
changing the overall conformation of Noxa in way that may facilitate
binding to the MOM through its MTD. In the absence of interaction
with Mcl-1 and A1, this conformational change may not occur and
perhaps the MTD of Noxa will not be properly oriented to insert in the
membrane. There is considerable evidence for this scenario, as will be
discussed in the following section. Third, BH3-only proteins may
target independently to the MOM by as yet unknown mechanisms,
and subsequently interact with their multi-region Bcl-2 partners.
Finally, it is still unclear if all BH3 proteins are really inserted into
membranes, or if some are peripheral membrane proteins and
therefore are located at speciﬁc intracellular organelles by binding
to other integral membrane proteins.
5. Bending into shape: does membrane binding cause functional
conformational changes in BH3-only proteins?
It is well established that both soluble and membrane inserted
multi-region Bcl-2 proteins change their three dimensional structure
to a new conformation to exert anti- or pro-apoptotic functions [39].
Soluble Bax and Bcl-XL must fold their respectiveα9 helices out of the
hydrophobic pocket of the protein so that the tail-anchor sequence
contained therein is available to insert into the membrane. The
membrane-resident members Bak and Bcl-2 change conformation
within the membrane after activation, as detected by exposure of a
neoantigen in the N-terminus of Bak [64,65], or a dramatic change in
the hydrophobic helices α5 and α6, respectively [41]. Similarly, both
Bak and Bax monomers must change conformation in the membrane
to form oligomers that permeabilize the membrane [22], although the
nature of this change is debated as will be discussed in a subsequent
section. There is some evidence that dynamic conformational
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The BH3-only protein Bid has also been shown to change its
conformation in themembrane after activation by caspase-8mediated
proteolysis [66].
Activation induced conformational changes may not be required
for those BH3-only proteins which are expressed only in the presence
of death stimuli. For example, after DNA damage, p53 induces the
transcription of its primary target PUMA, as well as Noxa and Bik
[60,67,68]. These proteins may be expressed in a “fully activated”
conformation that allows them to target to membranes by the various
mechanisms discussed in the previous section. However, constitu-
tively expressed BH3-only proteins are usually located in parts of the
cell distant from their target membrane(s) where they often
participate in functions independent of apoptosis [69]. For example,
functions in cell cycle regulation for Bid, and glucose metabolism for
Bad have been identiﬁed (reviewed in [70,71]). Post-translational
modiﬁcations may restrict the proteins to one of the alternative
functions. Full length Bid is phosphorylated at positions S61 and S78
in murine Bid, and S78 in human and rat Bid by ATM and ATR kinases
in response to DNA damage and replicative stress [72,73]. Casein
Kinase I and II also phosphorylate mouse Bid at S61 and S64, which
attenuates the caspase-8 mediated cleavage of Bid required for
activation for apoptosis [74]. Impaired caspase-8mediated cleavage of
S61 phosphorylated Bid ensures that Bid remains locked in its ‘non-
apoptotic’ conformation when it is regulating cell proliferation. Thus
we propose that phosphorylation of Bid acts as a switch for the
different functions of Bid. Although the structure of tBid solution
showed only minor differences compared to the structure of full-
length Bid [7], rearrangement of α6–8 helices was observed upon
binding to membranes [66]. Furthermore, based on the structural
similarities between Bid and multi-region Bcl-2 family proteins in
solution (reviewed in [5]), tBid likely undergoes extensive conforma-
tional changes upon insertion into the membrane. The Embedded
Together model [38,39] suggests that similar to Bax and Bcl-2, tBid
may adopt additional discrete conformations depending upon
whether it binds to pro-apoptotic or anti-apoptotic Bcl-2 proteins.
We propose that these conformations would determine whether tBid
promotes MOMP by directly activating Bax and Bak, or by sensitizing
Bcl-2 and Bcl-XL.
Unlike Bid, other constitutively expressed BH3-only proteins Bim,
Bad and Bmf are intrinsically unstructured in the absence of binding
partners, but undergo localized conformational changes in the BH3
region upon binding with anti-apoptotic proteins [9]. This inherent
structural plasticity may facilitate interactions with multiple binding
partners that permit the proteins to have ‘day jobs’ and still function
in the initiation of the apoptotic response. The most well character-
ized BH3-only protein with multiple binding partners is Bad. In
response to survival factors, Bad is sequestered by 14-3-3 chaperone
proteins [75]. Phosphorylation is the predominant molecular switch
that modulates interactions of Bad with the pro-survival proteins or
the 14-3-3 complex. Kinases whose activity mediates survival
phosphorylate murine Bad at three evolutionary conserved serine
residues, S112, S136 and S155 [75–78]. Residue S155 lies within the
BH3 region and by altering charge and size, phosphorylation disrupts
the interaction of Bad with the BH3-binding pocket of the anti-
apoptotic proteins Bcl-2, Bcl-XL and Bcl-W [76]. Thus phosphorylation
of Bad at multiple sites modiﬁes the BH3 region of Bad such that it
acquires a higher afﬁnity for the ubiquitous 14-3-3 chaperone
proteins. It is not clear in cells if Bad ﬁrst translocates to the MOM
spontaneously and then interacts with the anti-apoptotic proteins (as
this sequence has been observed in cell free systems), or if
interactions with the anti-apoptotic proteins mediate targeting to
membrane. Our model predicts that if Bad targets to the MOM
spontaneously (perhaps via a tail-anchor yet to be formally
identiﬁed), then membrane binding will trigger at least the tail-
anchor to become structured. Membrane binding may or may nottrigger folding of the rest of the protein but ultimately the ﬁnal
conformation of Bad will be reached only after interacting with both
the membrane and one of Bcl-2, Bcl-XL or Bcl-W.
A further level of complexity is present when studying Bim, which
similar to tBid, promotes MOMP directly by activating Bax and Bak,
and/or indirectly by inhibiting the anti-apoptotic proteins. We
postulate that although on its own it is constitutively unstructured,
Bim has four or more distinct conformations in the cell based on its
different functions: one that confers binding to microtubules, a tail-
anchored conformation that mediates insertion into the MOMprior to
binding other proteins, and two further membrane-bound conforma-
tions that depend on whether its binding partner is a pro- or anti-
apoptotic multi-region family member. There is intriguing circum-
stantial evidence for this proposition from several studies in the
literature. For example, when attached to liposomes via binding to Ni2
+ containing lipids, recombinant Bim-6xHis (without the endogenous
C-terminal sequence) is much less effective than tBid at activating Bax
[79]. This ﬁnding indicates that membrane binding is insufﬁcient and
a distinct conformation is required to properly orient the BH3 region
to activate Bax. Another study that provided evidence for distinct
modes of interaction of BH3-only molecules with pro- and anti-
apoptotic proteins used a Bim stapled peptide. With this structured
peptide, the authors identiﬁed a novel interaction site on Bax in an α1
and α6 helix containing region, distinct from the interaction site
previously identiﬁed for pro-survival molecules like Bcl-XL (see
below) [37]. As the stapled Bim peptide binds Bax but not Bcl-XL at
this location, this result is consistent with our proposal that binding to
the two classes of multi-region Bcl-2 proteins are mediated by
discrete conformations of the BH3-only proteins. We further propose
that Bim adopts these distinct conformations responsible for the
different functions in response to binding to membranes.
6. Activation of multi-region Bcl-2 proteins by BH3-only proteins:
kiss and run or kiss and stay?
Most experimental data suggests that BH3-only proteins bind the
anti-apoptotic proteins by docking on the BH3 region in the
hydrophobic groove made of BH1, BH2 and BH3 regions of the Bcl-2
like anti-apoptotic proteins [80]. Clear evidence of this interaction site
comes from the crystal structures of the BH3-region of Bim bound to
Bcl-XL [81] andMcl-1 [82], the BH3-region of Bid bound to Mcl-1 [83],
and BH3 regions of Puma, Bid and Bmf with A1 [84]. Despite strong
evidence for the functional interaction and activation of Bax and Bak
by activator BH3-only proteins, veriﬁcation for binding has been
minimal and inconsistent. Only the minor isoforms of Bim (BimS and
BimAD but not the more common BimEL and BimL) bind Bax in the
presence of detergents [27]. Although the hydrophobic groove that
mediates BH3 region binding in the anti-apoptotic Bcl-2 proteins is
also found in Bax and Bak, only one report has provided evidence for a
weak interaction between tBid BH3 region peptide and the hydro-
phobic groove of Bak in solution [85]. In contrast, strong binding of
tBid to Bax was observed for the full length proteins in membranes
(apparent Kd ~25 nM) [24].Thus, the data from liposomes support a
model in which there can be exchange of the subunits in the
mitochondrial membrane but clearly at steady statemost of the tBid is
bound to Bax or Bak (or an anti-apoptotic protein). However, when
both proteins are bound to membranes the hydrophobic groove
observed in the soluble form of Bax may not be the authentic site of
interaction. Therefore, other sites have been examined to determine
whether they can mediate BH3-only protein binding.
Using bacterial two-hybrid assays and co-immunoprecipitation in
human cell lines, the α1 helix in Bax was identiﬁed as an interaction
site for the BH3 regions of Bid and Puma [28]. Mutations in the BH3
region of Bid orα1 helix of Bax abolished tBid and Pumamediated Bax
activation suggesting that this interaction was necessary. The
orientation of α1 helix of Bax is akin to the BH4 containing α1 helix
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authors propose that the displacement of the α1 helix of Bax upon
binding the BH3 region of Bid, leads to structural instability of Bax
resulting in insertion in the membrane. One consequence of such a
change in Bax could be a conformational change for nearby residues,
accounting for the exposure of the 6A7 epitope during activation that
is recognized as one of the preliminary steps in the oligomerization
process.
As described above, Gavathiotis and coworkers reported the
identiﬁcation of a novel BH3 sequence binding site on Bax using a
stapled BH3 region peptide from Bim. In contrast to the other
proposals, this site encompassed α6, α1, α4 helices and the α1–α2
loop of Bax [37]. Since this newly identiﬁed BH3 region binding site on
Bax is on the “opposite” side of the protein to the hydrophobic groove
that is conventionally thought to bind to BH3 regions, we have termed
this the ‘rear’ pocket. In the ‘rear’ pocket, binding of the BH3 region
peptide allosterically induces a conformational change such as the
exposure of the amino-terminal 6A7 motif of Bax. However, it is
unclear if the BH3 stapled peptides recapitulate the physiological role
of full-length BH3-only proteins, and if this interaction in solution
reﬂects what happens in cells at membranes. Additionally, it is
uncertain if binding of BH3 stapled peptides with Bak would occupy
the corresponding ‘rear’ pocket. When the stapled BH3-peptide binds
to Bax in solution it displaces the α9 helix of Bax allowing it to insert
in membranes. In cells, Bak is already membrane-bound and the
corresponding ‘rear’ pocket is obstructed by the residues E32, R36 and
R156 making it difﬁcult for a BH3 peptide to bind at that site. We also
note that compared to the “ﬂoppy” α1–α2 loop in Bax, Bak contains a
small helix which is more ﬁxed due to nearby interactions, making it
difﬁcult to be displaced after binding to a BH3 peptide. Therefore, it is
possible that binding of BH3 peptide to the ‘rear pocket’ is only
relevant for Bax.Fig. 2.Mechanisms of Bax/Bak oligomerization inmembranes. Only Bax has been shown in th
transient interaction between an activator BH3-only protein and Bax/Bak, the BH3 region an
binding of BH3 region of one to the BH3 groove of another, and vice versa. The activator BH3-
molecule or after assisting in the formation of the dimer. Since both these sites get occupied
dimer interaction surface to form and subsequently enlarge the pore. B) In asymmetri
conformational changes in Bax/Bak to expose their BH3 regions. The exposed BH3 region of
The resulting Bax/Bak pore is asymmetrical because the BH3 region of one Bax molecule bind
can remain bound to the growing Bax pore in this model.The identiﬁcation of a ‘rear’ pocket binding site that initiates the
activation of Bax (and possibly Bak) has profound implications for
understanding the structure and process of Bax and Bak homo-
oligomerization, a step essential for MOMP. Consistent with a role for
the ‘rear’ pocket in Bax homo-oligomerization, a study using
photoactive cross-linking demonstrated Bax–Bax interactions in the
vicinity of both pockets when oligomerization was induced using
non-ionic detergents [87].
In a model proposed by Dewson and colleagues, after activation by
tBid, Bak everts its BH3 region revealing a hydrophobic groove which
ﬁts the exposed BH3 region of another Bak molecule to form a
‘symmetrical’ dimer [88]. Further evidence for direct BH3-BH3 contact
in Bax homo-oligomerization has been provided by [89,90]. Because
these Bak molecules would have “used up” their BH3 regions/binding
pockets to form the dimer, they must use another binding surface to
join with other dimers in forming oligomers. Through mutagenesis,
these investigators identiﬁed a site on the α6 helix of Bak that would
allow pre-formed adjacent dimers to join and extend the oligomer for
MOMP [64] (Fig. 2A). Presumably each dimer would have to be
individually assembled by tBid, another activator BH3 protein or an
activated Bak to expose the oligomerization site on α6. In this model,
the initiating BH3-only protein cannot be a stable part of the complex
as it would block homo-dimer formation. Accordingly in this model
BH3-only proteins function in a catalytic “kiss and run” fashion
activating multiple Bak dimers.
If the activation of Bax and Bak is initiated by the binding of the
BH3 protein to the ‘rear’ pocket, then by allostericmodiﬁcation of Bax/
Bak conformation, the same sequence may occur with eversion of the
BH3 region and the opening of the BH3 binding groove to allow
symmetric dimer formation. However, binding of a BH3 activator
protein to the ‘rear’ pocket is also compatible with a completely
different mode of oligomerization. Based on the auto-activatione schematics for simplicity. A) Themodel for symmetrical dimers proposes that through
d a BH3 groove are exposed in Bax/Bak. Two monomers of Bax/Bak bind each other by
only molecule falls off after either causing these conformational changes in the ﬁrst Bax
after forming a dimer, two dimers interact with each other through the exposure of a
cal dimers, activator BH3-only proteins bind Bax/Bak on the ‘rear’ pocket to cause
Bax/Bak can now act as an activator for other Bax/Bak molecules using auto-activation.
s to the ‘rear’ pocket of the next Bax molecule. Of note, the activator BH3-only molecule
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with its BH3 region exposed can now act like a ‘BH3-only molecule’
and can bind the rear pocket of another Bax to dislodge the α9 helix
and evert the BH3 region and groove. In this sense, the oligomer is
propagated “asymmetrically”, as each activated monomer has a BH3
region on one surface that binds to a ‘rear’ pocket of anothermonomer
on the opposite side (Fig. 2B). By this mechanism, activated Bax
molecules can undergo auto-activation to form Bax oligomers without
having to dissociate the initiating activator BH3-only molecule (also
reviewed in [38,40,93]. Additionally, oligomerization may reduce the
afﬁnity of the interaction between the initiating BH3-only molecule
and the oligomer. This weaker binding may account for difﬁculty of
detecting tBid-Bax complexes by immunoprecipitation of complexes
from solubilised cells, as the detergents commonly used (e.g. CHAPS)
have been shown to disrupt this interaction (Fig. 3 in [24]). Using
ﬂuorescence resonance energy transfer, a more direct assay that
avoids any detergents, we have shown that at equilibrium tBid
remains associated with Bax. Furthermore, this interaction can be
abolished by titration with unlabelled Bax demonstrating that the
subunits in the Bax pore are exchangeable and that tBid and Bax
display a direct but reversible interaction in the membrane [24].
Further insight can be gained into the mechanism of BH3 region
binding by examining the stoichiometry of activated Bax. Using
deﬁned concentrations of recombinant activator proteins, one mole-
cule of tBid or Bim recruits up to 20molecules of Bax to themembrane
[20,24] (unpublished data). This result is most easily explained by
transient binding of tBid or Bim to Bax, allowing one BH3-only
activator to activate several pro-apoptotic molecules. However, due to
the relatively tight binding of tBid with Bax in membranes, below a
certain threshold all of the tBid ismonopolized resulting in incomplete
Bax activation and membrane permeabilization (unpublished data).
Because the activated Bax in this circumstance apparently does not
mediate auto-activation, these results suggest that there may be
intermediate “activation complexes” of deﬁned stoichiometry that are
required to activate Bax.
A similar phenomenon has been reported for tBid and anti-
apoptotic Bcl-XL. Supra-stoichiometric quantities of Bcl-XL can be
recruited to the membrane by tBid or Bad — the ratio here is
approximately 4:1 [20,56] (unpublished results). However, unlike the
binding between tBid and Bax, stable complexes between membrane
bound tBid and Bcl-XL can be detected by immunoprecipitation.
Indeed, the stable binding of Bcl-XL to tBid to sequester it from
binding to and activating Bax is one of the mechanisms of action of
Bcl-XL. Thus in this case, the auto-activation of multiple Bcl-XL
molecules may enhance the anti-apoptotic function — a process that
we have described as tBid mediated activation of Bcl-XL.
Taken together, these results indicate that the interactions of BH3-
only proteins with pro- and anti-apoptotic multi-region Bcl-2 family
proteins can enhance or delay apoptosis depending on the relative
stoichiometry and afﬁnity of available partners in the membrane as
well as the extent to which auto-activation ampliﬁes each process.
Furthermore, small changes in membrane ﬂuidity are expected to
have large effects on the apparent afﬁnity of interactions within
membrane protein complexes. Clearly further investigation is re-
quired to fully understand how signalling by BH3-only proteins is
integrated at cellular membranes.
7. Too much of a bad thing: why are there so many BH3 proteins?
While there are approximately ﬁve anti-apoptotic and two main
pro-apoptotic multi-region proteins, there are at least ten different
BH3-only proteins in the vertebrate genome [4]. In C. elegans, there is
only one anti-apoptotic Bcl-2/Bcl-XL homologue, Ced-9, and two BH3
proteins, Egl-1 and Ced-13 [94]. The function of Egl-1 and Ced-13 is to
displace Ced-9 from Ced-4 so that the latter can activate Ced-3, the
caspase analogue. There are no homologues to the multi-region poreforming members Bax or Bak, and therefore the sensitizer rather than
the activator subgroup of mammalian BH3-only proteins is closer in
function to invertebrate homologues. Egl-1 and Ced-13 have over-
lapping but not identical biological functions. While Egl-1 regulates
developmentally programmed cell death in germ cells, as well as
death related to infection by pathogens and DNA damage, Ced-13 is
only involved in cell death in response to DNA damage [95]. Both are
regulated by complex transcriptional networks. Consequently, the
expansion of the BH3-only protein subgroup in vertebrates is likely
due to many linked features including: more cell types and therefore
more ﬂexibility needed to monitor different speciﬁc types of cell
damage; the presence of a complex and dynamic immune system that
both respond to cell death during development, and elicits cell death
in infected targets; the presence of multiple anti-apoptotic “targets”
such as, Bcl-2 and Mcl-1 with different BH3 binding grooves (and
therefore afﬁnities); and ﬁnally the additional ’opportunity’ to elicit
cell death directly by activating Bax or Bak to permeabilize
mitochondria.
The main consequence therefore, of the multiplicity of BH3-only
proteins is that it bestows the cell with versatile control over the
complex regulation of cell vitality in response to diverse damaging
stimuli. However, the principal of partial redundancy of signals and
responses to speciﬁc types of cellular damage seen with C. elegans is
still present in the larger group of vertebrate BH3-only proteins. For
example, Noxa and PUMA are both upregulated by p53 in response to
DNA damage [68], Bad and Bim both respond to growth factor
deprivation (reviewed in [71,96]), and Bim and Puma knock-out cells
are both insensitive to apoptosis induced by ER stress [29]. In a
healthy state, it appears that the cell employs transcriptional control
and post-translational modiﬁcations to limit the apoptotic functions
of BH3-only proteins, whereas receipt of diverse death signals release
these controls.
How important are these redundant controls in the context of the
whole organism? Bax/Bak double knock-out mice and mice in which
one of the pro-survival molecules like Bcl-2, Bcl-XL, or Mcl-1 are
knocked-out display various pathologic phenotypes or die as
embryos. In contrast, knock-out mice of individual BH3-only proteins
display more subtle abnormalities that can be speciﬁc to tissue-types
and organs (reviewed in [2]). Moreover, in conﬁrmation of the
signalling pathways identiﬁed in cell biological models, mice that do
not express individual BH3-only proteins have defects for some but
not all death stimuli (reviewed in [97]). Moreover, mice that lack one
of Bad, Bik, Hrk, Bmf or Noxa are normal in appearance and fertile. Bad
knock-out mice have a high incidence of lymphoma, and some cell
types display minor resistance to epidermal growth factor or insulin-
like growth factor deprivation [98]. Knock-in mice whose genome
encodes a mutant of Bad without the S112, S136 and S155
phosphorylation sites have defects in IL-7 dependent T-cell survival
[99]. Bid knock-out mice are resistant to Fas induced hepatocellular
apoptosis and fatal hepatitis [100]. However, Bid does not mediate all
signalling from death receptors as Bax is activated after treatment
with TNFα in Bid KO cells [101]. Loss of Noxa in ﬁbroblasts confers a
modest resistance to DNA damage induced apoptosis from etoposide
and radiation [68]. These ﬁndings are consistent with functional
redundancy but also demonstrate a certain degree of cell type/organ
speciﬁcity for the BH3-only proteins.
Parallel to the multiplicity of death signals mediated by BH3-only
proteins is the realization that these proteins in their “non-activated”
state have roles independent of apoptosis (and in the case of Bad, an
additional role in non-apoptotic cell death [102]). The speciﬁc role of
Beclin-1 at the interface of apoptosis and autophagy will be discussed
in more detail in the following section. The evolutionary logic and
history of these “duality of functions” is unclear: did the non-
apoptotic function precede the gain of a BH3 region that conferred a
speciﬁc pro-apoptotic function, or was the sequence reversed? The
evidence from speciﬁc knock-out mouse models has been only
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out Bid show defects in cell proliferation and altered G0–G1 transition,
consistent with its localization to both cytoplasm and the nucleus in
dividing cells [70,103]. A role for Bid in sensing DNA damage and
mediating cell cycle arrest has been proposed [72,73]. However, this
role is controversial as other authors have shown Bid to be
dispensable for DNA damage and replicative stress induced apoptosis
and cell cycle arrest [104].
Bad localizes to the cytoplasm and in vivo regulates glucose-driven
mitochondrial respiration, insulin secretion and glucose homeostasis
[105]. Bad has also been shown to promote cycle–cycle progression
during serum withdrawal or overexpression of anti-apoptotic
proteins [106]. Noxa appears to play a role in the maintenance of
memory CD4+ cells [107]. Bim and Bmf have been shown to localize
to the microtubules and actin ﬁlaments, respectively [96]. However, it
is not clear if these BH3-only proteins actually play a role in the
maintenance of these processes as their ‘day jobs’, because knock-out
mice show no abnormalities in these respective processes. Whether
this indicates that all these non-apoptotic functions are dispensable,
that adaptation obscures the effect of the knock-out or that
observational studies with mice may not indicate the importance of
these functions without speciﬁc stressors or circumstances will
require further investigation.
In addition to the recognized activator BH3-only proteins, other
types of proteins and even physical–chemical changes have been
shown to activate Bax and Bak. For example, the p53 tumour
suppressor has been shown to directly bind with Bax and activate it
in response to DNA damage independent of its role in transcription-
ally upregulating PUMA and Noxa [108]. Because it is possible that
p53 activates Bax by binding to sites distinct from those of the known
BH3-only activators; p53 may represent a class of activators that
cannot really be classiﬁed as BH3-only proteins. It has also been
reported that the CARD domain containing protein ASC acts as an
adapter for Bax activation with p53 [109]. Finally, an increase in either
acidity [110] or temperature [111] can induce the Bax conformational
change associated with activation of the protein in cells. This diverse
range of activators suggests that Bax (and Bak) are like coiled springs
that can be ‘released’ to assume the pore-forming conformation by
small perturbations at multiple trigger points. As such, it seems likely
that there are more activators of Bax and Bak yet to be discovered.
Given the short sequence length and the minimal essential sequence
features it may also be that many more proteins contain functional
BH3 regions.8. Do BH3-only proteins have multiple workplaces in apoptosis?
It is well documented that many BH3-only proteins localize to
MOM to promote apoptosis. However, Bcl-2 is normally targeted to
multiple intracellular membranes, and a form of Bcl-2 targeted
speciﬁcally to the ER efﬁciently inhibits selective forms of apoptosis
[112,113]. At the ER, Bcl-2 can directly inhibit Bax and/or Bak, both of
which have also been demonstrated to be present in this organelle
[41]. However, consistent with our proposal that Bcl-XL inhibits
mitochondrial permeabilization via multiple mechanisms including
recruiting and binding to BH3-only proteins, many BH3 proteins bind
to anti-apoptotic Bcl-2 family members at the ER. For example, in a
variety of different cell lines, Bik, Bad and Beclin-1 have been
identiﬁed as ER associated proteins. It is possible that these or other
BH3 proteins sequestered by Bcl-XL at the ER are mediators of a cell
death response that requires MOMP, and that therefore this site of
action is still connected to, but upstream of the canonical apoptotic
pathway. Alternatively when localized at the ER, BH3 proteins may
mediate a pathway of cell death that does not require MOMP. There is
evidence that different BH3-only proteins realize either or both these
possibilities.The ER lumen serves as a storage site for Ca2+ and as a site for the
folding and modiﬁcation of proteins. Depletion of ER calcium stalls
protein folding by calcium dependent ER chaperons like calnexin and
calreticulin, and prevents protein export from the ER. These changes
(and others such as oxidative stress, and inhibition of glycosylation)
increase the burden of misfolded proteins within the ER lumen and
can elicit the unfolded protein response (UPR) [114]. Although the
immediate effect of the various effector arms of the UPR (including
activation of ATF-6, IRE-1 and PRK-1) is to decrease the protein
folding burden by decreasing translation and increasing chaperone
proteins, persistent UPR leads to apoptosis [115]. Cell lines lacking
both Bax and Bak have higher than normal concentrations of
intraluminal ER Ca2+, and when Bax or Bak is speciﬁcally targeted
to the ER, the cells die presumably because of abnormal Ca2+ ﬂux
[116]. It is most likely that the replacement of the tail-anchor
sequence to localize Bax or Bak to the ER exclusively also results in
spontaneous activation of the proteins. However, it is formally
possible that over-expression in the ER generates an apoptotic signal
that leads to activation via an interaction with a BH3-activator. At
present it is unclear which activator BH3-only proteins are respon-
sible for the oligomerization of Bax or Bak at the ER. Nevertheless,
there are multiple examples of BH3-only proteins that potentially
function at the ER. Puma and Noxa have been shown initiate Ca2+
release from the ER [117]. Bim can be upregulated by the ER-stress
responsive transcription factor CHOP by virtue of a speciﬁc binding
site in the promoter of Bim [118]. In this case, the ER stress related cell
death would ultimately be mediated by MOMP. There is also a
connection between ER andmitochondrial cell death pathways that is
independent of ER calcium [45]. ER stress induces the activation of
caspase-2 which cleaves and activates Bid [119]. In all these cases, the
BH3-only proteins are not speciﬁcally localized to the ER. A special
case is provided by Bik, a BH3-only protein with a tail-anchor
sequence that mediates selective integration into the ER membrane
[45,67]. Bik has been shown to induce ER resident Bax/Bak to release
Ca2+ which can then lead to the release of cytochrome c [120].
Aside from these pathways in which ER stress leads to MOMP, the
Bcl-2 family of proteins also regulate autophagy which functions as a
separate cell death vs. survival pathway that is initiated at the ER.
Autophagy is a catabolic pathway required for the degradation of
proteins, cytoplasmic organelles and intracellular pathogens. The
process of autophagy involves the sequestration of cytoplasmic
constituents and intracellular organelles within newly generated
double membrane vesicles called autophagosomes, which are then
delivered to and fuse with lysosomes for degradation and recycling of
their contents [121]. Cells maintain a low basal rate of autophagy to
maintain homeostasis. In response to stress signals caused by
decreased intracellular metabolite concentrations, autophagy pre-
vents cell death by replenishing metabolites [122]; however,
autophagy can also cause cell death.
During autophagy, the ER-associated platform for the initial
formation of pre-autophagosomal vesicles is called the omegasome
[123]. This platform is created when vesicles containing Vps34, a class
III phosphatidylinositol 3-kinase, assemble in a complex isolated with
Beclin-1. It is believed that Beclin-1 links autophagy and apoptosis
because Beclin-1 was originally identiﬁed as a Bcl-2 binding protein
in a yeast two-hybrid screen [124]. The BH3-region of Beclin-1 binds
to Bcl-2 and Bcl-XL, thus Beclin-1 is a bona ﬁde member of the BH3-
only family [125–128]. Studies have shown that Bcl-2 targeted to the
ER but not the MOM inhibits starvation-induced autophagy [126].
This suggests that binding of Bcl-2 to Beclin-1 prevents it from
assembling the omegasome. It has also been shown that the BH3-only
protein, Bad and the Bad mimetic drug ABT-737 can disrupt the
Beclin-1–Bcl-2/Bcl-XL complex to restore autophagy [128]. This
regulatory mechanism is consistent with the direct activation
model, in which BH3 sensitizers (Bad) displace BH3 activators
(Beclin-1) from the anti-apoptotic proteins. In this case the activator
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binding afﬁnity of the sensitizer Bad to Bcl-2 is greater than the
respective activators, tBid or Beclin-1. The consequence of Beclin-1
displacement may be to change its conformation such that the
inhibitory factor Rubicon no longer binds to the nascent omegasome
complex, and the recruitment of proteins to membranes required to
initiate autophagy can proceed. The binding of Bcl-2 to Beclin-1 is
markedly enhanced in the presence of the recently characterized
factor NAF-1 [129]. Furthermore the interaction between Bcl-2 and
the IP3 receptor that controls Ca2+ release from the ER is also
dependent on NAF-1 [129,130].
Thus BH3-only proteins resident at the ER are critical regulators of
multiple functions that determine cell fate, either upstream of their
role in activating MOMP (Puma, Noxa, Bik, Bid) or in the case of
Beclin-1 and autophagy, independent of other BH3 protein functions.
That the regulation of autophagic cell death as opposed to autophagy
mediated cell survival is biologically relevant is underscored by the
observation that genetically Beclin-1 functions as a haplo-insufﬁcient
tumour suppressor [131]. How autophagy eventually kills the cell and
the identity of the switch between autophagic survival and cell death
still remains unknown.
9. Are BH3-only proteins the key to successful cancer therapy?
Inhibition of apoptosis is involved in the development of cancers as
well as resistance to treatment thus, there is a great interest in
developing agents that restore the process. Given the pedigree
described here, it is not surprising that much effort has been
expended to ﬁnd small molecules that mimic BH3-only protein
function as novel anti-cancer agents (also see [93]). The recognition of
the control of the commitment step of apoptosis by the Bcl-2 family
led to a highly useful scheme to identify three possible blocks that
cancer cells can exploit: loss of BH3-only proteins (or inhibition of
their activation), a reduction or elimination of multi-region pro-
apoptotic proteins, and increased expression of an apoptosis inhibitor
such as Bcl-2 or Mcl-1 [132]. Examples of each block have been noted
in different cancer types.
Renal carcinoma cells transcriptionally repress the expression of
Bik through DNA methylation [133]. Interestingly, failure to express
Bim was also observed, suggesting that co-ordinate dysregulation of
BH3-only proteins could nullify multiple death signals. B-cell non-
Hodgkin lymphoma derived cell lines also showed inactivation of BH3
proteins through diverse mechanisms. In mantle cell lymphoma the
Bim gene was deleted, in Burkitt lymphoma the Bim promoter was
hypermethylated, and in diffuse large B-cell lymphoma the Noxa gene
was both mutated and preferentially silenced [134]. The Puma gene
was deleted in 3131 cancer specimens analysed by high resolution
somatic copy-number alterations [135].
The Bax gene is inactivated by microsatellite instability and
deletion in haemopoietic cell lines and colon cancer cell lines
[136,137], and thus functions as a tumour suppressor. In addition,
the Bok gene, another multi-region pro-apoptotic Bcl-2 family
member similar to Bax and Bak, is deleted in many cancer specimens
[135]. However, the most widespread block noted to date in human
cancers is the overexpression of anti-apoptotic proteins [11,31,135].
Tumours are often described as being “primed” for death since they
are dependent on or “addicted to” the presence of one or more anti-
apoptotic protein for survival [14,15]. Directly inhibiting the interac-
tion between the anti-apoptotic proteins and BH3 proteins is a
strategy to initiate cell death that should be selective to these addicted
cancer cells. A new technique called BH3 proﬁling has been introduced
to specify the anti-apoptotic protein that is responsible for the block
by exploiting the speciﬁcity of the binding pattern of BH3-only
proteins with anti-apoptotic proteins [11,14]. Isolated mitochondria
from the cancer cells are exposed to peptides derived from the BH3
region of BH3-only proteins, and the release of cytochrome c ismeasured as indication of the displacement of a BH3 activator protein
by the peptide [11,14]. By using a combination of peptides that
discriminate between different anti-apoptotic proteins the relevant
one can be identiﬁed. For example, it has been shown that CLL
samples depend on Bcl-2 rather than Mcl-1 [15].
Extending the concept of BH3 proﬁling of mitochondria with
peptides to treating the whole cancer patient with drugs that mimic
BH3 peptides is becoming a promising anti-cancer strategy. In
tumours with the loss or inhibition of BH3-only proteins, BH3
mimetics replace the need to induce expression or activate BH3-
only proteins to initiate death. On the other hand, in cancers over-
expressing anti-apoptotic Bcl-2 family proteins, BH3 mimetics can
compete with endogenous activator BH3-only proteins for binding to
anti-apoptotic proteins. The released activator BH3-proteins can then
initiate apoptosis via interactions with Bax and Bak. Since the BH3
regions are relatively small (14–24 amino acids), it has also been
possible to design and synthesize or identify small molecules that can
function as peptide mimics [138]. However, the limitations of low
bioavailability, poor uptake, solubility and stability of peptides means
that both chemical and peptide based peptide mimetics must be
addressed [139]. Several advances have been made to improve the
pharmacological properties of peptide based peptide mimetics. For
example, chemically stapled BH3 peptides have increased stability,
are protease resistant, and have better cellular uptake and increased
afﬁnity for binding to Bcl-2 family proteins [23]. The attachment of a
fatty acid to a cell permeable Bad BH3 peptide can induce apoptosis in
vitro [140].
The chemical inhibitor ABT-737 was developed by Abbott
Laboratories using a nuclear magnetic resonance (NMR)-based screen
to identify Bcl-2 inhibitors [141]. The hydrophobic binding groove of
Bcl-XL was divided into two smaller binding sites, and each
individually targeted by small molecules. The two small molecules
were chemically linked andmodiﬁed to form ABT-737. ABT-737 binds
to Bcl-XL, Bcl-2 and Bcl-W but not to Mcl-1 and A1 [141]. The crystal
structure of Bcl-XL and ABT-737 complex shows that ABT-737 most
closely resembles the Bad BH3 region [142], and therefore displaces
both Bad and Bim from the binding pocket of Bcl-2 [15]. ABT-737 also
disrupts the interaction of Beclin-1 with Bcl-2 and Bcl-XL, thus
resulting in autophagy [128]. Cancer cells with higher levels of Bcl-2
and Bcl-XL, but lower levels of Mcl-1 are sensitive to ABT-737 [15].
These features were also noted for the orally bioavailable derivative
ABT-263 which is currently being tested in multiple clinical trials
[143]. Because ABT-737 and ABT-263 do not bind Mcl-1, Mcl-1
expression is the determinant of resistance to ABT-737 in many
different cell lines [15,132,144]. By using an RNAi-based screen Mcl-1
was conﬁrmed as themost important source of resistance in small cell
lung cancer [145]. Because resistance can be reversed by reducing
Mcl-1 levels [144] it may be that combination of ABT-263 with an
inhibitor of Mcl-1 will permit a selective kill of a wide variety of
tumours.
Obatoclax is a synthetic indol bipyrrol derivate developed by
Gemin X Biotechnologies. It was identiﬁed from a screen of small
molecules that disrupt protein–protein interactions of the Bcl-2
family members. Obatoclax binds to Bcl-XL, Bcl-W, and Mcl-1 [146],
and disrupts the interaction between Mcl-1 and Bak to overcome
resistance to ABT-737 [147]. However, obatoclax can also kill Bax/Bak
double knock out cells [148], suggesting that in some situations off-
target effects may be responsible for cell death. Most recently, it has
been shown that obatoclax disrupts the interaction between Mcl-1
and Beclin-1 and leads to Bax/Bak independent autophagic cell death
in acute lymphoblastic leukemia cell lines and patient samples [149].
If this phenomenon is more general in cancer, it may be a way to
exploit the non-mitochondrial cell death alluded to in the previous
section for important therapeutic purposes.
The development of new BH3 mimetics that can target Mcl-1 and
A1 to circumvent the observed resistance of many of the BH3mimetic
517A. Shamas-Din et al. / Biochimica et Biophysica Acta 1813 (2011) 508–520drugs is an important priority. The scope of the problem is
demonstrated by a recent structural analysis of the hydrophobic
grooves of Mcl-1 compared to Bcl-XL. The hydrophobic pocket of Bcl-
XL is ﬂexible and therefore creates a pliable pocket for diverse BH3
mimetics, whereas the hydrophobic pocket of Mcl-1 is deeper with a
rigid ‘angle of entry’. This explains why Mcl-1 cannot adopt a
conformation that binds to ABT-737 or related derivatives [150].
Therefore, rationally designing BH3 mimetics against Mcl-1 based on
the speciﬁc binding requirements to the hydrophobic pocket of Mcl-1
is a likely way forward. As starting points the BH3 regions of Bid and
Noxa bind to Mcl-1 and A1 [11,14,16]. As an alternative strategy,
enhancing the already short half life of the Mcl-1 protein is being
investigated by multiple approaches [151,152].
To date all BH3 mimetic drugs have been screened against soluble
protein fragments of anti-apoptotic Bcl-2 family members. However,
it is increasingly clear that both pro- and anti-apoptotic family
members change conformation extensively after insertion into
membranes — their physiologic site of action in cells [18,21,22,41].
Therefore, designing an activator with high binding afﬁnity for Bax
and Bak in the membranewould be a direct way to promote apoptosis
in cancer cells that are already primed for death. Similarly, designing
an inhibitor with high binding afﬁnity for the membrane embedded
forms of anti-apoptotic proteins may lead to more potent and
selective therapy.10. Summary
BH3-only proteins receive multiple death signals from inside and
outside of the cell and relay this information to multi-region Bcl-2
proteins to induce apoptosis. Most BH3-only proteins are predicted to
bind to MOM through their C-terminus using a tail-anchor or other
sequences that target the protein to membranes. The diverse
apoptotic and non-apoptotic functions of BH3-only proteins are
regulated by transcriptional, post-transcriptional and post-transla-
tional modiﬁcations. After binding to theMOM, BH3-only proteins can
bind to and thereby cause the insertion into membranes of both pro-
or anti-apoptotic Bcl-2 family proteins. We speculate that BH3-only
proteins mediate these opposing functions by multiple distinct
conformational changes: ﬁrst by binding to the membrane and
subsequently while forming hetero-dimers with the different types of
multi-region Bcl-2 family proteins. Interaction of the anti-apoptotic
proteins with BH3-only protein in turn may result in two unique
conformations of the anti-apoptotic proteins in the membrane, one
that inhibits Bax/Bak activation and one that is inactivated for this
function. Activation of Bax and Bak by activator BH3-only proteins
also causes conformational changes that allow them to insert and
permeabilize MOM. The large number of BH3-only proteins allows the
cell to control initiation of apoptosis signalling at multiple “entry
points”. Furthermore, tissue speciﬁc expression and the balance
between sensitivity to a limited number of stimuli with partial overlap
allow BH3-only proteins to impart speciﬁc signalswithminimal cross-
talk. In addition to MOM, BH3-only proteins localize to ER and initiate
ER mediated mitochondrial dependent and independent cell death.
Since BH3-only proteins bind both the anti- and pro-multi-region Bcl-
2 proteins, BH3-mimetics that selectively antagonize the anti-
apoptotic proteins may prove to be successful in cancer therapy.Acknowledgements
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